Ert Batten Brineura denied as not medically necessary by Cigna?

Cigna's specific coverage criteria for ert batten brineura are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Brineura (cerliponase alfa) on Medical-Necessity Grounds

Brineura is an enzyme replacement therapy approved for a rare, progressive pediatric neurological disorder — CLN2 disease, a form of Batten disease. Cigna's medical-necessity denials in this category typically reflect one or more concerns: whether the diagnosis has been confirmed through the required genetic and enzymatic testing, whether disease severity and rate of progression have been adequately documented, or whether the prescribing center meets Cigna's requirements for specialist oversight of an ultra-rare condition.

These denials are almost always appealable. CLN2 disease is rapidly progressive and has no other approved disease-modifying treatment, which means delays caused by administrative denials carry real clinical consequence. That urgency is a core argument in your appeal.

## Federal Appeal Rights

If your plan is an ACA-governed fully-insured or self-funded plan that has opted in to external review, you have the right to an independent external review under ACA Section 2719. ERISA-governed plans must also provide a full-and-fair review process under ERISA Section 503. The standard internal-appeal deadline is typically 180 days from the denial notice. After exhausting internal appeals, you may request external review. If the clinical situation is urgent, request an expedited appeal and expedited external review simultaneously — the timelines compress to days rather than months.

## Appeal Process and Timeline

1. Internal Level 1 appeal — submit within the plan's stated deadline (often 180 days). Expect a decision within 30 days for non-urgent requests, 72 hours for expedited. 2. Internal Level 2 appeal (if the plan offers one) — an additional layer reviewed by a different clinical reviewer. 3. External review — after internal exhaustion (or simultaneously if urgent), request an Independent Review Organization (IRO) determination. Most states mandate a final decision within 45 days; expedited external review within 72 hours.

## Documentation to Gather

• Confirmed diagnosis: genetic sequencing report confirming CLN2 pathogenic variant(s) AND enzyme activity assay results from a qualified laboratory.
• Clinical severity and progression: neurologist notes documenting current motor and language assessment scores (e.g., CLN2 Clinical Rating Scale or equivalent) at multiple time points to demonstrate the rate of decline.
• Prior-treatment history: record of any supportive or symptomatic therapies tried, with dates and outcomes.
• Prescriber medical-necessity letter: written by the treating pediatric neurologist or metabolic specialist, explicitly stating that the patient meets the FDA-approved indication as described in the prescribing label and that no adequate alternative exists.
• Specialist center documentation: confirmation that care is being coordinated at or with a center experienced in CLN2/Batten disease management, if Cigna's policy requires it.

## Criteria-Mapping Structure

Pull Cigna's published medical policy for Brineura/cerliponase alfa from Cigna's coverage policy library. List every requirement in that policy. For each requirement, cite the exact chart finding, lab report, or clinical note that satisfies it. Do the same for the FDA-approved prescribing label. This point-by-point mapping is the most effective format for a rare-disease medical-necessity appeal because it removes ambiguity and forces the reviewer to address each criterion explicitly.